Probiotics Boost Weight Loss and Metabolic Benefits of GLP-1 Agonists
Background
Obesity and metabolic syndrome are global health crises, often managed with Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) like semaglutide, which are effective but can have variable responses and side effects. The gut microbiome is increasingly recognized for its profound influence on host metabolism and drug efficacy. This study investigated whether specific energy-metabolism-enhancing probiotics could augment the therapeutic benefits of GLP-1 RAs and improve metabolic outcomes.